Early-stage Breast Cancer
Conditions
Brief summary
The main purpose of this study is to evaluate the quality of life of premenopausal participants with Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor-2 (HER2) negative breast cancer who are receiving, in addition to triptorelin, an endocrine cancer treatment. The study will also get more information about: - the effectiveness and safety of triptorelin; - the relationship that could exist between the characteristics of the disease and the treatment chosen by the Investigator.
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
: * Premenopausal (as per local definition) female patients aged ≥18 years on the day the informed consent is signed; * Patients have histologically proven, HR-positive and HER2 negative breast cancer according to local definition, determined by immunohistochemistry, and up to stage IIIA. Note: patients with synchronous bilateral breast cancer and patients with breast cancer (BRCA)1/2 gene mutations are eligible; * Patients have been prescribed adjuvant endocrine treatment with TAM or an AI plus triptorelin (either the 1 month or 3 month formulation) by their treating physician or, in alternative, triptorelin given in combination or consequent to neoadjuvant/adjuvant chemotherapy. Note: the decision to prescribe triptorelin is made by the treating physician prior to and independently of the decision to enroll the patient in this study; * Patients must be documented to be disease-free at enrolment, as determined by the treating physician according to institutional standards. Note: in case the patient has been prescribed neoadjuvant treatment, the patient will receive surgery and be enrolled but will only remain in the study if disease-free condition is confirmed after surgery. If this condition is not confirmed, then the patient will be discontinued from the study; * Written informed consent for trial participation must be signed and dated by the patient and the Investigator prior to enrolment; * Patients have been informed of and agree to data transfer and handling, in accordance with national data protection guidelines; * Patients must be accessible for follow-up; * Patients may have received previous treatment with triptorelin for another indication, but the last administration must have occurred at least 6 months before enrolment.
Exclusion criteria
: * Patient is currently enrolled in any other clinical study or has participated in one within the 12 weeks prior to the Inclusion visit, or is scheduled to receive a new investigational drug while this study is ongoing; * Patient is not eligible for triptorelin treatment as guided by the product's label in Italy due to safety concerns or has prior history of no responsiveness to triptorelin (in case of previous triptorelin treatment); * Patient has premenopausal status that cannot be defined; * Patient has had bilateral oophorectomy or ovarian irradiation; * Patient has current loco-regional relapse and/or distant metastatic disease; * Patient has a history of prior (ipsi- and/or contralateral) invasive breast cancer; * Patient has a history of malignancy other than invasive breast cancer, with the following exceptions: (a) Patients diagnosed, treated and disease-free for at least 5 years and deemed by the Investigator to be at low risk for recurrence of that malignancy are eligible; (b) Patients with the following malignancies are eligible, even if diagnosed and treated within the past 5 years: in situ breast ductal carcinoma; in situ cervical cancer; in situ thyroid cancer; nonmetastatic, no melanomatous skin cancers; * Patient has concurrent disease or condition that would make study participation inappropriate or any serious medical disorder that would interfere with the patient's safety; * Patient has psychiatric, addictive, or any other disorder that would prevent compliance with protocol requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants reaching a clinically significant change in the global Quality of Life (QoL) score. | At 18 months. | Defined as a minimum change of ≥4 points using the Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tumor characteristics. | At baseline. | — |
| Percentage of days covered of compliance | At 18 months | — |
| Description of breast cancer treatment. | At baseline. | Including triptorelin formulation (1-month or 3-month formulation), planned neoadjuvant/adjuvant chemotherapy (yes/no) and oral adjuvant endocrine treatment prescribed ((Aromatase Inhibitor (AI) or Tamoxifen (TAM)) |
| Identification of potential demographic factors predictive of any treatment switch. | At 18 months. | A multivariate logistic regression will be used to identify demographic factors predictive of any treatment switches. |
| Identification of demographic and tumor characteristics correlated to the entire prescribed breast cancer treatment. | At 18 months. | A multivariate logistic regression will be used to identify characteristics correlated to the prescription of the 1-month or 3-month triptorelin formulations with TAM or an AI. |
| Proportion of participants who switch between triptorelin formulations, from AI to TAM or vice-versa, or undergo both triptorelin and adjuvant therapy switches | At 18 months. | The switches between triptorelin formulation or from the AI to TAM will be described together with the reasons for switches. |
| Proportion of disease-free participants. | At 18 months. | Disease-free survival is defined as the time from triptorelin initiation to disease recurrence as determined by the Investigator. |
| Proportion of participants alive. | At 18 months. | The OS rate will be estimated using the Kaplan-Meier method. Survival time will be defined as the time from triptorelin initiation to participant's death for any reason. |
| Proportion of compliant patients (100% of the planned injections) to triptorelin | At 18 months. | — |
| Identification of potential demographic, tumor-related or breast cancer treatment-related factors predictive of suboptimal OFS. | At 18 months. | as per local definition, or empirically defined as E2 levels ranging between 30 and 70 pg/ml according to the average range collected in Italian centers. A multivariate logistic regression will be used to identify predictive factors of suboptimal OFS as per local definition |
| Identification of potential demographic, tumor-related or breast cancer treatment-related factors predictive of clinically significant global QoL change | At 6, 12 and 18 months. | A multivariate logistic regression will be used to identify any predictive factors of clinically significant global QoL change (i.e. ≥4 points). |
| Incidence of all treatment-emergent adverse events (TEAEs) | From baseline up to 18 months. | Summary incidence tables of nonserious and serious AEs, as well as special situations presented overall, by System Organ Class and Preferred term (MedDRA coding) and according to intensity and causality |
| Change in the Quality of Life (QoL) score using the FACT-G questionnaire with the Endocrine Symptoms (ES) subscale. | From baseline and at 6, 12 and 18 months | All global scores and subscores of the QoL questionnaire will be described at each timepoint. Comparisons will be performed using the paired Student t-test. |
| Description of demographic data. | At baseline. | Including age at diagnosis, parity, pregnancy desire (yes/no), oocyte cryopreservation (yes/no) and embryo cryopreservation (yes/no); |
| Description of demographic data | At baseline. | Including Body Mass Index calculation |
| Proportion of participants with hormonal levels (E1, E2 and FSH) corresponding to Ovarian Function Suppression (OFS) | From baseline up to 18 months. | As per local definition, or empirically defined as E2 levels \<30 pg/ml according to the average level collected in Italian centers) |
Countries
Italy
Contacts
STUDY_DIRECTORIpsen Medical, Director
Ipsen
Outcome results
None listed